Results 261 to 270 of about 885,175 (334)

Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab

Dagmar von Bubnoff, Christina Schmitt, Simone M. Goldinger, Dirk Schadendorf, Katharina C. Kähler, Christian Hafner, Nora Kramer, Waltraud Fröhlich, Reinhard Dummer, Carola Berking, Stefan Schliep, Michael Constantin Kirchberger, Lucie Heinzerling   +12 more
openalex   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Metastatic Melanoma to Ovary and Advances in Metastatic Melanoma Treatment: A Case Report. [PDF]

Cureus
Cantave M, Chen AH, Carrubba AR, Robertson M.   +3 more
europepmc   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

BMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo, Nan Li, Daiwei Zhang, Jingya Gu, Zhihuan Liao, Zihao Teng, Xiangfu Du, Peter S. Timashev, Shipeng Chen, Shuaidong Huo   +9 more
wiley   +1 more source

Gut markers for metastatic melanoma receiving immunotherapy. [PDF]

BMC Cancer
Ou G, Gou J, Ou H, Zheng H, Zhu Y, Li J, Liu X.   +6 more
europepmc   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

ASO Author Reflections: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma. [PDF]

Ann Surg Oncol
Farooq MS, Shafique N, Karakousis GC.
europepmc   +1 more source

Nanogel‐Mediated Immunotherapy to Tackle Cancer and Inflammatory Diseases

ChemistryEurope, EarlyView.
Nanogels formed through self‐assembly, microemulsion, or precipitation polymerization method enable precise delivery of immunotherapeutic factors and immune cell targeting, thus effectively modulating immune responses. This review highlights recent advances in stimuli‐responsive nanogel design, underlying mechanisms, and their potentials to tackle ...
Ziwen Zhang, Jinxia Wang, Guang‐Zhi Jin, István Bányai, Dzmitry Shcharbin, Ivan Stoikov, Mingwu Shen, Xiangyang Shi   +7 more
wiley   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Idiosyncratic Drug-Induced Liver Injury in a Patient With Metastatic Melanoma. [PDF]

Cureus
Ottley A, Thornton A, Gil R, Sardinas G.
europepmc   +1 more source